Studies on the metabolism and toxicological detection of the new psychoactive designer drug 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe) in human and rat urine using GC-MS, LC-MSn, and LC-HR-MS/MS

[1]  D. Boels,et al.  Elucidation of the metabolites of the novel psychoactive substance 4-methyl-N-ethyl-cathinone (4-MEC) in human urine and pooled liver microsomes by GC-MS and LC-HR-MS/MS techniques and of its detectability by GC-MS or LC-MS(n) standard screening approaches. , 2015, Drug testing and analysis.

[2]  M. Meyer,et al.  Benzofuran analogues of amphetamine and methamphetamine: studies on the metabolism and toxicological analysis of 5-APB and 5-MAPB in urine and plasma using GC-MS and LC-(HR)-MSn techniques , 2015, Analytical and Bioanalytical Chemistry.

[3]  C. Wolf,et al.  Determination of 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication. , 2014, Drug testing and analysis.

[4]  M. Meyer,et al.  Toxicokinetics of novel psychoactive substances: characterization of N-acetyltransferase (NAT) isoenzymes involved in the phase II metabolism of 2C designer drugs. , 2014, Toxicology letters.

[5]  T. Mak,et al.  Two cases of severe intoxication associated with analytically confirmed use of the novel psychoactive substances 25B-NBOMe and 25C-NBOMe , 2014, Clinical toxicology.

[6]  M. Meyer,et al.  Methylenedioxy designer drugs: mass spectrometric characterization of their glutathione conjugates by means of liquid chromatography-high-resolution mass spectrometry/mass spectrometry and studies on their glutathionyl transferase inhibition potency. , 2014, Analytica chimica acta.

[7]  Morna L Gonsoulin,et al.  Pathological Findings in 2 Cases of Fatal 25I-NBOMe Toxicity , 2014, The American journal of forensic medicine and pathology.

[8]  C. Hegarty,et al.  2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe): Clinical Case with Unique Confirmatory Testing , 2014, Journal of Medical Toxicology.

[9]  M. Meyer,et al.  Dimethocaine, a synthetic cocaine analogue: studies on its in-vivo metabolism and its detectability in urine by means of a rat model and liquid chromatography–linear ion-trap (high-resolution) mass spectrometry , 2014, Analytical and Bioanalytical Chemistry.

[10]  H. Bräuner‐Osborne,et al.  Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists. , 2014, ACS chemical neuroscience.

[11]  C. Wolf,et al.  High-performance liquid chromatography tandem mass spectrometry method for the determination of 2CC-NBOMe and 25I-NBOMe in human serum. , 2013, Biomedical chromatography : BMC.

[12]  Hans H Maurer,et al.  What is the future of (ultra) high performance liquid chromatography coupled to low and high resolution mass spectrometry for toxicological drug screening? , 2013, Journal of chromatography. A.

[13]  S. R. Rose,et al.  A case of 25I-NBOMe (25-I) intoxication: a new potent 5-HT2A agonist designer drug , 2013, Clinical toxicology.

[14]  M. Meyer,et al.  2-Methiopropamine, a thiophene analogue of methamphetamine: studies on its metabolism and detectability in the rat and human using GC-MS and LC-(HR)-MS techniques , 2013, Analytical and Bioanalytical Chemistry.

[15]  M. Meyer,et al.  Drugs of abuse screening in urine as part of a metabolite-based LC-MSn screening concept , 2011, Analytical and bioanalytical chemistry.

[16]  Jerry Zweigenbaum,et al.  Development and practical application of a library of CID accurate mass spectra of more than 2,500 toxic compounds for systematic toxicological analysis by LC–QTOF-MS with data-dependent acquisition , 2011, Analytical and bioanalytical chemistry.

[17]  M. Meyer,et al.  Development of the first metabolite-based LC-MSn urine drug screening procedure-exemplified for antidepressants , 2011, Analytical and bioanalytical chemistry.

[18]  H. Maurer.  Chemistry, Pharmacology, and Metabolism of Emerging Drugs of Abuse , 2010, Therapeutic drug monitoring.

[19]  J. McNeill,et al.  To scale or not to scale: the principles of dose extrapolation , 2009, British journal of pharmacology.

[20]  H. Maurer,et al.  Studies on the toxicological detection of the designer drug 4-bromo-2,5-dimethoxy-beta-phenethylamine (2C-B) in rat urine using gas chromatography-mass spectrometry. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[21]  H. Maurer,et al.  Identification of monoamine oxidase and cytochrome P450 isoenzymes involved in the deamination of phenethylamine-derived designer drugs (2C-series). , 2007, Biochemical pharmacology.

[22]  Michael R. Braden,et al.  Molecular Interaction of Serotonin 5-HT2A Receptor Residues Phe339(6.51) and Phe340(6.52) with Superpotent N-Benzyl Phenethylamine Agonists , 2006, Molecular Pharmacology.

[23]  H. Maurer,et al.  Studies on the metabolism and toxicological detection of the designer drug 2,5‐dimethoxy‐4‐methyl‐β‐ phenethylamine (2C‐D) in rat urine using gas chromatographic/mass spectrometric techniques , 2006 .

[24]  H. Maurer,et al.  Studies on the metabolism and toxicological detection of the designer drug 4-ethyl-2,5-dimethoxy-beta-phenethylamine (2C-E) in rat urine using gas chromatographic-mass spectrometric techniques. , 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[25]  M. Pütz,et al.  New designer drug 4-iodo-2,5-dimethoxy-beta-phenethylamine (2C-I): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric and capillary electrophoretic/mass spectrometric techniques. , 2006, Journal of mass spectrometry : JMS.

[26]  J. Poklis,et al.  Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death. , 2014, Forensic science international.

[27]  M. Meyer,et al.  Biotransformation and detectability of the designer drug 2,5-dimethoxy-4-propylphenethylamine (2C-P) studied in urine by GC-MS, LC-MSn, and LC-high-resolution-MSn , 2014, Analytical and Bioanalytical Chemistry.

[28]  H. Maurer.  How can analytical diagnostics in clinical toxicology be successfully performed today? , 2012, Therapeutic drug monitoring.

[29]  H. Maurer,et al.  Studies on the metabolism and toxicological detection of the designer drug 2,5-dimethoxy-4-methyl-beta- phenethylamine (2C-D) in rat urine using gas chromatographic/mass spectrometric techniques. , 2006, Journal of mass spectrometry : JMS.

[30]  H. Maurer,et al.  New designer drug, 2,5-dimethoxy-4-propylthio-beta-phenethylamine (2C-T-7): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. , 2005, Journal of mass spectrometry : JMS.